This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Statement of Retraction: MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRNA modifications and cancer · Ferroptosis and cancer prognosis · Cancer-related gene regulation
We, the Editor and Publisher of Bioengineered, have retracted the following article:
Jie Yan, Litong Shi, Shan Lin & Yi Li (2021) MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel, Bioengineered, 12:1, 5334-5347, DOI: 10.1080/21655979.2021.1938497
Following publication, the authors reached out to inform the journal in 2023 that they could not verify the data within the article. They stated that some of the experiments within the article were assisted by a third party and that the reported results could no longer be relied upon. The use of a third party to perform experiments was not disclosed within the article.
As we cannot verify the validity of the published work or that it complied with our editorial policies, we are therefore retracting the article. The authors listed in this publication have been informed.
We have been informed in our decision-making by our editorial policies and the COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.